...
首页> 外文期刊>Epilepsia Open >Exome sequencing identifies molecular diagnosis in children with drug‐resistant epilepsy
【24h】

Exome sequencing identifies molecular diagnosis in children with drug‐resistant epilepsy

机译:外显子组测序可确定耐药性癫痫患儿的分子诊断

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective Early onset drug‐resistant epilepsy is a neurologic disorder in which 2 antiepileptic drugs fail to maintain the seizure‐free status of the patient. Heterogeneous clinical presentations make the diagnosis challenging. We aim to identify the underlying genetic causes of a pediatric cohort with drug‐resistant epilepsy and evaluate whether the findings can provide information on patient management. Methods We include patients with drug‐resistant epilepsy onset before 18?years of age. Singleton clinical chromosomal microarray (CMA) followed by whole exome sequencing (WES) was performed using genomic DNA. In the first‐tier analysis of the exome data, we aimed to identify disease‐causing mutations in 546 genes known to cause, or to be associated with, epilepsy. For negative cases, we proceeded to exome‐wide analysis. Rare coding variants were interrogated for pathogenicity based on the American College of Medical Genetics and Genomics (ACMG) guidelines. Results We recruited 50 patients. We identified 6 pathogenic or likely pathogenic mutations, giving a diagnostic yield of 12%. Mutations were found in 6 different genes: SCN8A , SCN1A , MECP2 , CDKL5 , DEPDC5 , and CHD2 . The CDKL5 variant was found to be mosaic. One variant of unknown significance (VUS) in KCNT1 was found in a patient with compatible clinical features. Of note, a reported pathogenic SCN5A mutation known to contribute to Brugada syndrome, was also found in the patient with an SCN1A mutation. Significance Our study suggests that singleton WES is an effective diagnostic tool for drug‐resistant epilepsy. Genetic diagnosis can help to consolidate the clinical diagnosis, to facilitate phenotypic expansion, and to influence treatment and management options for seizure control in our patients. In our study, a significant portion of the genetic findings are known to be associated with an increased risk of sudden unexpected death in epilepsy (SUDEP). These findings could assist with more appropriate management in patients with epilepsy.
机译:目的早期发作的耐药性癫痫是一种神经系统疾病,其中2种抗癫痫药无法维持患者的无癫痫发作状态。异构的临床表现使诊断具有挑战性。我们旨在确定耐药性癫痫患儿队列的潜在遗传原因,并评估研究结果是否可以提供有关患者管理的信息。方法我们纳入了18岁之前有耐药性癫痫发作的患者。使用基因组DNA进行单例临床染色体微阵列(CMA),然后进行全外显子组测序(WES)。在外显子组数据的第一层分析中,我们旨在鉴定已知导致癫痫或与癫痫相关的546个基因中的致病突变。对于阴性病例,我们进行了全基因组分析。根据美国医学遗传学和基因组学学院(ACMG)指南,对罕见的编码变体进行了致病性研究。结果我们招募了50名患者。我们确定了6个病原体或可能的病原体突变,诊断率为12%。在6个不同的基因中发现了突变:SCN8A,SCN1A,MECP2,CDKL5,DEPDC5和CHD2。发现CDKL5变体是镶嵌的。在具有兼容临床特征的患者中发现了KCNT1中一种未知意义(VUS)的变体。值得注意的是,在患有SCN1A突变的患者中也发现了已知导致Brugada综合征的致病性SCN5A突变。重要性我们的研究表明,单例WES是耐药性癫痫的有效诊断工具。遗传诊断可以帮助巩固临床诊断,促进表型扩展,并影响患者癫痫发作控制的治疗和管理选择。在我们的研究中,已知遗传学发现中有很大一部分与癫痫突然猝死(SUDEP)的风险增加有关。这些发现可能有助于癫痫患者更适当的治疗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号